# Luteoloside (Luteolin 7-O-glucoside)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/luteoloside
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-30
**Evidence Score:** 4 / 10
**Category:** Compound
**Also Known As:** Luteolin 7-O-glucoside, Luteolin 7-glucoside, Luteolin-7-O-β-D-glucopyranoside, 7-Glucosylluteolin, Luteolin 7-O-β-glucoside, Cynaroside

## Overview

Luteoloside, also called luteolin 7-O-glucoside, is a flavone glycoside found in plants such as peanut hulls, celery, and perilla leaves, where luteolin is bound to glucose at the 7-position for improved water solubility. Its primary mechanisms include inhibition of NF-κB signaling and activation of SIRT1, driving [anti-inflammatory](/ingredients/condition/inflammation) and antifibrotic effects documented in preclinical models.

## Health Benefits

• [Anti-inflammatory](/ingredients/condition/inflammation) effects: Reduced inflammatory pain and cytokine levels (IL-1β) in mouse models at 20-80 mg/kg doses (preclinical evidence only)
• Pulmonary fibrosis protection: Demonstrated reduced lung fibrosis and [oxidative stress](/ingredients/condition/antioxidant) via SIRT1 activation in bleomycin-induced mouse models (PMID: 41162593, animal study)
• Anti-cancer properties: Inhibited cervical cancer cell proliferation and induced apoptosis through MAPK/mTOR pathways (in vitro evidence only)
• [Neuroprotective](/ingredients/condition/cognitive) potential: Suppressed neuroinflammation markers and microglial activation in preclinical pain models (animal evidence)
• [Cellular senescence](/ingredients/condition/longevity) prevention: Reduced age-related cell markers in pulmonary tissues through SIRT1 pathway (preclinical models only)

## Mechanism of Action

Luteoloside suppresses the NF-κB signaling pathway, reducing transcription of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s including IL-1β, TNF-α, and IL-6. It activates the NAD-dependent deacetylase SIRT1, which in turn downregulates TGF-β1-driven fibroblast activation and collagen deposition, explaining its antifibrotic activity in lung tissue. Additionally, it scavenges [reactive oxygen species](/ingredients/condition/antioxidant) and upregulates endogenous antioxidant enzymes such as superoxide dismutase and catalase, reducing oxidative stress markers.

## Clinical Summary

Available evidence for luteoloside is currently limited to in vitro cell studies and rodent in vivo models; no published human clinical trials exist for this specific glycoside form. In bleomycin-induced pulmonary fibrosis mouse models, luteoloside reduced lung hydroxyproline content and [oxidative stress](/ingredients/condition/antioxidant) markers via SIRT1 activation. [Anti-inflammatory](/ingredients/condition/inflammation) studies in mouse models used doses of 20–80 mg/kg, demonstrating significant reductions in IL-1β and inflammatory pain behaviors compared to controls. The translation of these preclinical findings to human efficacy and safe dosing ranges has not yet been established.

## Nutritional Profile

Luteoloside (Luteolin 7-O-glucoside) is a flavone glycoside, not a macronutrient source. It is a pure bioactive compound with molecular formula C21H20O11 and molecular weight of 448.38 g/mol. It consists of the flavone aglycone luteolin attached to a glucose moiety at the 7-position via a glycosidic bond. As a compound rather than a food, it contains no meaningful protein, fat, or fiber content. Key bioactive characteristics: flavone backbone with hydroxyl groups at positions 3', 4', 5, and 7, conferring [antioxidant](/ingredients/condition/antioxidant) capacity. Naturally occurring in chrysanthemum flowers (Chrysanthemum morifolium) at concentrations ranging approximately 0.5–8 mg/g dry weight depending on cultivar and extraction method; also found in peanut hulls, celery, and various herbs. Bioavailability is limited by the glycosidic bond — intestinal and microbial beta-glucosidases cleave glucose to release free luteolin in the gut, with absorption primarily in the small intestine and colon. Oral bioavailability of luteolin-type flavones is generally estimated at 3–10% in humans based on pharmacokinetic studies. Peak plasma concentrations in rodent studies at 20–80 mg/kg doses show detectable serum levels within 1–2 hours post-administration. Undergoes hepatic phase II [metabolism](/ingredients/condition/weight-management) (glucuronidation, sulfation, methylation). No established Dietary Reference Intake (DRI) or Recommended Daily Allowance (RDA) exists; it is not classified as an essential nutrient. Micronutrient content is not applicable as this is an isolated phytochemical compound.

## Dosage & Preparation

No human dosage data available. Preclinical mouse studies used intraperitoneal doses of 20-80 mg/kg, with peak effects at 2 hours and sustained benefits after 13-14 daily doses. All studies used pure luteoloside powder (>98% purity) rather than plant extracts. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

No formal human safety or toxicology studies have been conducted specifically on luteoloside, making definitive side-effect and interaction profiles unavailable. As a flavone glycoside structurally related to luteolin, it may share luteolin's potential to inhibit cytochrome P450 enzymes (particularly CYP1A2 and CYP2C8), which could theoretically alter [metabolism](/ingredients/condition/weight-management) of co-administered drugs such as warfarin or statins. Pregnant and breastfeeding individuals should avoid supplemental use due to a complete absence of safety data in these populations. Individuals on anticoagulant or anti-platelet medications should exercise caution given the [anti-inflammatory](/ingredients/condition/inflammation) and potential platelet-modulating properties of flavonoids in this class.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for luteoloside. All available evidence comes from preclinical studies including mouse [inflammatory](/ingredients/condition/inflammation) pain models (20-80 mg/kg IP doses), bleomycin-induced pulmonary fibrosis models (PMID: 41162593), and in vitro cancer cell studies. Human dental pulp cell studies also showed protective effects against methylglyoxal damage (PMID: 38505968).

## Historical & Cultural Context

No information on historical or traditional medicinal uses of luteoloside was found in available research. Current data focuses exclusively on modern pharmacological research conducted since recent decades.

## Synergistic Combinations

Celecoxib (low-dose), SIRT1 activators, PPARγ agonists, Nrf2 activators, [Anti-inflammatory](/ingredients/condition/inflammation) compounds

## Frequently Asked Questions

### What is the difference between luteoloside and luteolin?

Luteoloside is the glycosylated form of luteolin, meaning a glucose molecule is attached at the 7-position of the luteolin flavone backbone, forming luteolin 7-O-glucoside. This glycosylation significantly increases water solubility compared to aglycone luteolin, though intestinal enzymes must cleave the glucose moiety before or after absorption, potentially affecting bioavailability and pharmacokinetics differently than free luteolin.

### What foods contain luteoloside naturally?

Luteoloside occurs naturally in peanut hulls, celery (Apium graveolens), perilla leaves (Shiso), artichoke, and several traditional medicinal herbs including Chrysanthemum morifolium. Concentrations vary considerably by plant part and preparation method, with peanut hulls and perilla representing some of the richer documented dietary sources studied in extraction research.

### What dose of luteoloside was used in anti-inflammatory studies?

Preclinical mouse model studies investigating luteoloside's anti-inflammatory effects used oral or intraperitoneal doses in the range of 20–80 mg/kg body weight, producing measurable reductions in IL-1β levels and inflammatory pain behaviors. These rodent doses cannot be directly extrapolated to human equivalents without allometric scaling and clinical validation, and no human dosing guidelines currently exist.

### Can luteoloside help with lung fibrosis?

In bleomycin-induced pulmonary fibrosis mouse models, luteoloside demonstrated reduced lung collagen deposition, lower hydroxyproline content, and decreased oxidative stress markers, with the mechanism linked to activation of the SIRT1 deacetylase pathway suppressing TGF-β1-driven fibroblast activity. However, these findings are strictly preclinical, and no human trials have tested luteoloside for pulmonary fibrosis, so clinical conclusions cannot be drawn at this time.

### Is luteoloside safe to take with blood thinners like warfarin?

No human drug interaction studies exist for luteoloside specifically, but as a flavonoid it may inhibit hepatic CYP2C8 and CYP1A2 enzymes involved in warfarin metabolism, potentially increasing warfarin exposure and bleeding risk. Until formal interaction data are available, individuals taking anticoagulants such as warfarin or direct oral anticoagulants should consult a healthcare provider before using any luteoloside-containing supplement.

### How is luteoloside absorbed and metabolized in the body?

Luteoloside is a glycoside form of luteolin, meaning it contains a glucose molecule attached that must be removed by gut bacteria or intestinal enzymes before absorption can occur. This glucoside structure affects bioavailability compared to free luteolin, as the compound must first be deglycosylated in the intestine. Once the glucose is cleaved, luteolin is absorbed through the small intestine and undergoes hepatic metabolism. The bioavailability of luteoloside from dietary sources remains lower than aglycone luteolin due to this required enzymatic processing step.

### What is the current evidence quality for luteoloside's health benefits?

The evidence for luteoloside is primarily preclinical, limited to laboratory and animal studies in mice examining anti-inflammatory, anti-fibrotic, and anti-cancer properties. No large-scale human clinical trials have been published establishing efficacy or optimal dosing in people. While animal models show promise for pulmonary fibrosis and inflammatory conditions at 20-80 mg/kg doses, these results cannot be directly extrapolated to human supplement recommendations. More human research is needed before luteoloside can be considered evidence-based for treating specific health conditions.

### Who should avoid luteoloside supplementation or use it cautiously?

Individuals taking anticoagulant medications (blood thinners) should consult a healthcare provider before using luteoloside supplements, as flavonoids may have mild antiplatelet effects. Pregnant and nursing women should avoid luteoloside supplementation due to lack of safety data in these populations. People with hormone-sensitive conditions should exercise caution, as flavonoids like luteoloside may have weak estrogenic activity. Those preparing for surgery should discontinue luteoloside at least 2 weeks prior due to potential bleeding risk.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*